Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 27Lung Neoplasms 7Non Small Cell Lung Cancer Metastatic 3Neoplasm Metastasis 3Recurrence 2Advanced Non-Small Cell Lung Cancer 2ALK Positive Non-small Cell Lung Cancer 2Sexual Dysfunction, Physiological 1Non-Small Cell Lung Cancer ALK-positive 1Non Small Cell Lung Cancer ALK Positive or ROS1 Positive 1Neurofibromatosis 1 1Neoplasms 1Neoadjuvant Non-Small Cell Lung Cancer 1NSCLC 1Meningeal Carcinomatosis 1Lung Diseases 1Hyperlipidemias 1Hereditary Sensory and Autonomic Neuropathies 1Eunuchism 1Erectile Dysfunction 1Colorectal Neoplasms 1Brain Neoplasms 1Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer 1Adenocarcinoma of Lung 1ALK-positive Non-small Cell Lung Cancer 1ALK-positive NSCLC 1

Interventions

Crizotinib 2lorlatinib 1ceritinib 1brigatinib 1alectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
ALK-positive NSCLC × lorlatinib × Thoracic × Clear all
NCT04647110 2023-04-06

Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.

Pfizer

Completed
549 enrolled 28 charts
Thoracic

ALK-positive NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡